CT-guided (125)I brachytherapy in the treatment of distant metastases in the oral cavity and maxillofacial region.

PURPOSE: We aimed to evaluate the feasibility and clinical effectiveness of CT-guided (125)I brachytherapy for distant oral and maxillofacial metastases.

MATERIALS AND METHODS: We retrospectively analyzed 65 patients with 84 distant oral and maxillofacial metastases. Thirty-one patients with 38 lesions received (125)I brachytherapy (group A) and 34 with 46 lesions received external beam radiotherapy (EBRT; group B).

RESULTS: Median follow-up time was 16 months. The 3-, 6-, 12-, 18-, and 24-month local control rates for group A were 83.9%, 75.9%, 66.7%, 38.4%, and 25.0%, respectively; for group B they were 76.5%, 62.5%, 43.8%, 25.0%, and 0.0%, respectively (P<.05); the median local tumor progression-free survival times were 14 and 9 months, respectively. Group A had a better local tumor progression-free survival (LTPFS) relative to group B (P<.001; HR, 6.961 [95%CI, 2.109, 9.356]). Cox proportional hazards regression analysis indicated that (125)I brachytherapy, tumor size, and primary pathological type were the independent factors affecting LTPFS. Additionally, (125)I brachytherapy showed better performance in relieving patient clinical symptoms relative to EBRT (P<.05). Group A also had fewer complications than group B, especially regarding grade 3/4 complications according to Radiation Therapy Oncology Group grading criteria. Mean overall survival times in groups A and B were 17.1 and 14.8 months, respectively.

CONCLUSION: CT-guided (125)I brachytherapy is feasible and safe for distant oral and maxillofacial metastases; it achieved a better local control rate, longer LTPFS and fewer complications without compromising overall survival compared with EBRT.